DGAP-Media / 2020-02-21 / 13:41
· _Numerous talks and posters on sphingotec's acute care biomarkers in the
scientific program of the conference _
· _sphingotec to host symposium "Relevant Pathways, Novel Diagnostic and
Therapeutic Approaches in Acute Organ Dysfunction"_
*Hennigsdorf, Germany, February 21, 2020* - SphingoTec GmbH ("sphingotec")
today announced that novel data on its acute care biomarkers Proenkephalin
(penKid(R)) and Dipeptidyl Peptidase 3 (DPP3) will be presented at the 25th
International Conference on Advances in Critical Care Nephrology (AKI & CRRT
2020) taking place in San Diego, CA, USA, on February 24-27, 2020.
*AKI & CCRT 2020 Presentations on penKid(R) and DPP3 *
In the scientific program of the conference, clinical researchers will
present the latest results from studies investigating these two critical
care biomarkers and their utility in diagnosing kidney injury. In a session
on translating biomarker discoveries to clinical care, Peter Pickkers
(Radboud University | RU · Department of Intensive Care, Nijmegen, The
Netherlands) will present data demonstrating that sphingotec's kidney
function marker penKid(R) is a reliable surrogate for assessing true
glomerular filtration rate (true GFR) in patients with renal insufficiency.
Previous studies demonstrated that penKid(R) is a real-time kidney function
biomarker, which is independent of inflammation and other co-morbidities. In
another session, Matthieu Legrand (University of California, San Francisco |
UCSF · Department of Anesthesia and Perioperative Care, USA) will provide
evidence showing that sphingotec's biomarker DPP3 is one cause for
short-term kidney dysfunction and is highly associated with the development
of acute kidney injury (AKI) in patients with severe burns. Being at the
core of a newly discovered disease mechanism, DPP3 has been shown to play a
causal role in short-term organ dysfunction when released into the
bloodstream upon massive cell death in several acute and critical care
conditions.
*Sphingotec Symposium at AKI & CCRT 2020*
In a symposium organized by sphingotec titled "Relevant Pathways, Novel
Diagnostic and Therapeutic Approaches in Acute Organ Dysfunction" leading
clinical researchers will further discuss pathways leading to acute organ
dysfunctions in critically ill patients as well as a novel diagnostic
solution to assess the involvement of such pathways in acute and critical
care conditions. Beyond providing an overview of novel biomarkers for
monitoring kidney function, endothelial function, and DPP3-mediated heart
and kidney dysfunction, the speakers will also share findings that are
qualifying these biomarkers as biotargets. ###
*Oral Presentations at AKI & CRRT 2020*
· Session: Bench to Bedside: Translating Discoveries to Clinical Care,
February 24, 2020
"Proenkephalin: Is it the New GFR Marker?" presented by Peter Pickkers
(Radboud University | RU · Department of Intensive Care)
· Session: Acute Kidney Injury (AKI): Pathophysiology, February 25, 2020
"DPP3 in Critical Illness: Another Piece of the Puzzle" presented by
Matthieu Legrand (University of California, San Francisco | UCSF ·
Department of Anesthesia and Perioperative Care)
*Poster Presentation at AKI & CRRT 2020*
· *Title*: Proenkephalin, a Novel Biomarker for Kidney Function, is
Earlier in Detecting Acute Kidney Injury Compared to Creatinine.
*Authors* R Beunders, M Meekes, J Struck, P Pickkers
· *Title:* Proenkephalin Predicts Renal Dysfunction, Organ Failures, Renal
Replacement Therapy, and Mortality in Sepsis
*Authors* H Kim, M Hur, J Struck, A Bergmann, S Di Somma
· *Title:* penKid Proenkephalin A 119-159 effectively predicts Acute
Kidney Injury, Multiple Organ Failure, Mortality particularly among septic
patients at the ER with seemingly intact renal function
*Authors* M Rosenqvist, K Bronton, O Hartmann, A Bergmann, J Struck & O
Melander
*About sphingotec *
SphingoTec GmbH ("sphingotec"; Hennigsdorf near Berlin, Germany) develops
and markets innovative in vitro diagnostic (IVD) tests for novel and
proprietary biomarkers for the diagnosis, prediction and monitoring of acute
medical conditions, such as sepsis, acute heart failure, circulatory shock,
and acute kidney injury in order to support patient management and provide
guidance for treatment strategies. sphingotec's proprietary biomarker
portfolio includes Bioactive Adrenomedullin (bio-ADM(R)), a unique biomarker
for real-time assessment of endothelial function in conditions like sepsis
or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker
for real-time assessment of kidney function, and Dipeptidyl Peptidase 3
(DPP3), a unique biomarker for cardio-renal pathway disruptions leading to
acute organ dysfunction. In addition, sphingotec develops a portfolio of
novel biomarkers, which predict the risks of developing obesity, breast
cancer and cardiovascular diseases. IVD tests for sphingotec's proprietary
biomarkers are made available as sphingotest(R) microtiterplate tests as
well as point-of-care tests on the Nexus IB10 immunoassay platform by
sphingotec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad
menu of IB10 tests for established biomarkers for acute and critical care.
*Contact *
SphingoTec GmbH
Ruxandra Lenz
Neuendorfstr. 15 A
16761 Hennigsdorf
Germany
Tel. +49-3302-20565-0
press@sphingotec.de
www.sphingotec.com
End of Media Release
Issuer: SphingoTec GmbH
Key word(s): Health
2020-02-21 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
981023 2020-02-21
(END) Dow Jones Newswires
February 21, 2020 07:41 ET (12:41 GMT)
